Sarepta Therapeutics Inc (SRPT)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$36.40

Buy

$36.66

arrow-down$-0.25 (-0.68%)

Prices updated at 10 May 2025, 00:56 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.
NASDAQ
arrow-up0%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
-
CEO
Mr. Douglas S. Ingram,Esq.
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,372
Head office
215 First Street
Cambridge
United States
02142
mobile
+1 617 274-4000
letter
iestepan@sarepta.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Ms. Deirdre P. Connelly
Independent Director
0.02m
Mr. Douglas S. Ingram,Esq.
Director, President and Chief Executive Officer
0.85m
Dr. M. Kathleen Behrens Wilsey, PhD
Chairwoman of the Board
0.13m
Dr. Claude Nicaise,M.D.
Independent Director
0.08m
Dr. Hans Wigzell, M.D.,PhD
Independent Director
0.09m
Mr. Richard J. Barry
Independent Director
0.11m
Dr. Kathryn Jean Boor, PhD
Independent Director
0.08m
Ms. Louise Rodino-Klapac
Executive Vice President, Head of R&D and Chief Scientific Officer
0.67m
Mr. Ian Michael Estepan
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.66m
Dr. Stephen L. Mayo, PhD
Independent Director
0.08m
Mr. Michael A. Chambers
Independent Director
0.07m
Mr. Bilal Arif
Executive Vice President and Chief Technical Operations Officer
0.55m
Mr. Dallan Murray
Executive Vice President and Chief Customer Officer
0.62m
Mr. Cristin Rothfuss
Executive Vice President, Chief General Counsel and Corporate Secretary
-

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
BlackRock Inc11,191,986
Vanguard Group Inc9,085,456
Capital Research & Mgmt Co - Division 38,697,137
Capital Research and Management Company8,449,932
Capital Group8,130,005

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
27 Dec 2024-
12 Dec 2024-
12 Dec 2024-
12 Dec 2024-
05 Dec 2024-
26 Nov 2024-
26 Nov 2024-
18 Nov 2024-
12 Sep 2024-
12 Sep 2024-
04 Sep 2024-
30 Aug 2024-
16 Aug 2024-
16 Aug 2024-
16 Aug 2024-
03 Jul 2024-
03 Jul 2024-
21 Jun 2024-
21 Jun 2024-
21 Jun 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.